{"id":53522,"date":"2023-02-01T15:02:44","date_gmt":"2023-02-01T14:02:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/"},"modified":"2023-02-01T15:02:44","modified_gmt":"2023-02-01T14:02:44","slug":"jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/","title":{"rendered":"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor"},"content":{"rendered":"
\n

LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae<\/sup>, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Eli Lilly to be a specialty pharmacy partner for JAYPIRCA\u2122 (pirtobrutinib), which is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton\u2019s tyrosine kinase inhibitor (BTKi). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOnco360 is excited to announce our partnership with Eli Lilly and become a specialty pharmacy provider for JAYPIRCA patients,\u201d said Benito Fernandez, Chief Commercial Officer, Onco360. \u201cWe are committed to supporting the highly specialized needs of patients battling relapsed\/refractory mantle cell lymphoma which has failed prior lines of systemic therapy across the United States.\u201d\n<\/p>\n

\nAccording to the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) program, it is estimated that 80,470 new cases of Non-Hodgkin Lymphoma (NHL) will be diagnosed in 2022 in the United States with a corresponding 20,250 deaths in 2022.1<\/sup> According to the National Comprehensive Cancer Network (NCCN) Guidelines for the Treatment of B-Cell Lymphomas, 3-5% of annual new NHL diagnoses are mantle cell lymphoma (MCL) cases. MCL is thought to possess the unfavorable characteristics of both indolent and aggressive NHL subtypes owing to the incurability of disease with conventional chemotherapy and a typically more aggressive disease course compared to indolent lymphomas. The five-year overall survival (OS) for MCL ranges from 50-70% dependent upon stage of disease.2<\/sup>\n<\/p>\n

\nJAYPIRCA, a non-covalent BTKi, is commercialized by Eli Lilly. The FDA approval of JAYPIRCA is based on results Phase I\/II BRUIN trial (NCT03740529), which was an open-label, single-arm study that, in part, evaluated the efficacy\/safety of JAYPIRCA in 120 patients with relapsed\/refractory MCL who were previously treated with BTKi therapy. JAYPIRCA administration resulted in a 50% overall response rate (ORR) in the aforementioned patient population. The most common adverse reactions (><\/span> 15%) in patients with MCL are fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.3<\/sup>\n<\/p>\n

\nAbout Onco360 Oncology Pharmacy:<\/b>\n<\/p>\n

\nOnco360 is the nation\u2019s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com<\/a>.\n<\/p>\n

\nReferences:\n<\/p>\n

\n1) Non-Hodgkin Lymphoma \u2014 Cancer Stat Facts<\/a> accessed 1\/30\/23
\n
2) b-cell.pdf (nccn.org)<\/a> accessed 1\/30\/23
\n
3) Mantle Cell Lympoma (MCL) Treatment | Jaypirca\u2122 (pirtobrutinib)<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Benito Fernandez, Chief Commercial Officer
\n
benito.fernandez@onco360.com<\/a>
516-640-1332\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Eli Lilly to be a specialty pharmacy partner for JAYPIRCA\u2122 (pirtobrutinib), which is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53522","6":"format-standard","7":"category-industry"},"yoast_head":"\nJAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Eli Lilly to be a specialty pharmacy partner for JAYPIRCA\u2122 (pirtobrutinib), which is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T14:02:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230201005230\/en\/799936\/21\/Onco_360.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor\",\"datePublished\":\"2023-02-01T14:02:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/\"},\"wordCount\":519,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005230\\\/en\\\/799936\\\/21\\\/Onco_360.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/\",\"name\":\"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005230\\\/en\\\/799936\\\/21\\\/Onco_360.jpg\",\"datePublished\":\"2023-02-01T14:02:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005230\\\/en\\\/799936\\\/21\\\/Onco_360.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005230\\\/en\\\/799936\\\/21\\\/Onco_360.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/","og_locale":"en_US","og_type":"article","og_title":"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor - Pharma Trend","og_description":"LOUISVILLE, Ky.–(BUSINESS WIRE)–Onco360\u00ae, the nation\u2019s leading independent Specialty Pharmacy, has been selected by Eli Lilly to be a specialty pharmacy partner for JAYPIRCA\u2122 (pirtobrutinib), which is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-01T14:02:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230201005230\/en\/799936\/21\/Onco_360.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor","datePublished":"2023-02-01T14:02:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/"},"wordCount":519,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005230\/en\/799936\/21\/Onco_360.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/","url":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/","name":"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005230\/en\/799936\/21\/Onco_360.jpg","datePublished":"2023-02-01T14:02:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230201005230\/en\/799936\/21\/Onco_360.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230201005230\/en\/799936\/21\/Onco_360.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/jaypirca-pirtobrutinib-now-available-from-onco360-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-lines-of-systemic-therapy-in\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"JAYPIRCA\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53522"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53522\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}